As antibodies blocking the interaction of PD-1 expressed on tumor-infiltrating lymphocytes (TILs) including natural killer (NK) and T cells, the effective application of both ICB agents requires further information about the susceptibility of the tumor towards ICB, based on the expression of the targeted antigen PD-1 [10]. This evidence concerns the gene PDCD1 and neoplasm.